Home › Companies › CRBU

Caribou Biosciences

CRBU Lead: Phase 3 3 Biotech Distilled articles ↓

Oncology Cell

Most recent annual filing: 2026-03-05

Pipeline (4 active programs)

vispacabtagene regedleucel

vispa-cel · CB-010

Cell Target: CD19

CB-011

Cell Target: BCMA

Relapsed/Refractory Multiple Myeloma Phase 1

Technology platforms

chRDNA

CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology using hybrid guides containing both RNA and DNA for editing genomic DNA; enables high-specificity multiplex genome editing for ex vivo allogeneic CAR-T cell therapies; focus areas include oncology and autoimmune diseases

Discontinued (2)

vispacabtagene regedleucel — Lupus · discontinued GALLOP phase 1 trial prior to dosing the first patient as part of strategic pipeline prioritization
CB-012 — Relapsed/Refractory Acute Myeloid Leukemia · discontinued AMpLify phase 1 clinical trial as additional data would be needed to advance this program; license agreement with MSKCC terminated

Biotech Distilled coverage (3)

2026-06-11 UPDATE: Caribou Biosciences (CRBU) - The Durability Box Gets Checked
2026-05-08 UPDATE: Caribou Biosciences (CRBU) - The FDA Said Yes, The Bank Account Said “About That...” 🔒 Paid
2026-04-17 Caribou Biosciences (CRBU) - Scientific Deep Dive for Vispa-cel and CB-011 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.